1. Name and Address of Reporting Person: CATHERS BRIAN EDWIN

   (Last) (First) (Middle)
   C/O GLOBAL BLOOD THERAPEUTICS, INC.
   181 OYSTER POINT BOULEVARD

2. Issuer Name and Ticker or Trading Symbol: Global Blood Therapeutics, Inc. [GBT]

3. Date of Earliest Transaction (Month/Day/Year): 09/01/2020

4. If Amendment, Date of Original Filed (Month/Day/Year): 

5. Relationship of Reporting Person(s) to Issuer:
   Director, 10% Owner
   Chief Scientific Officer

6. Individual or Joint/Group Filing (Check Applicable Line):
   Form filed by One Reporting Person

Ohio Global Blood Therapeutics, Inc.

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>1. Title of Security (Instr. 3)</th>
<th>2. Transaction Date (Month/Day/Year)</th>
<th>2A. Deemed Execution Date, if any (Month/Day/Year)</th>
<th>3. Transaction Code (Instr. 8)</th>
<th>4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)</th>
<th>5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)</th>
<th>6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>7. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>09/01/2020</td>
<td></td>
<td>M</td>
<td>3,750</td>
<td>A (1)</td>
<td>8,994 D</td>
<td></td>
</tr>
<tr>
<td>Common Stock</td>
<td>09/01/2020</td>
<td></td>
<td>F</td>
<td>1,551 (2)</td>
<td>D $60.45</td>
<td>7,443 D</td>
<td></td>
</tr>
</tbody>
</table>

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

<table>
<thead>
<tr>
<th>1. Title of Derivative Security (Instr. 3)</th>
<th>2. Conversion or Exercise Price of Derivative Security</th>
<th>3. Transaction Date (Month/Day/Year)</th>
<th>3A. Deemed Execution Date, if any (Month/Day/Year)</th>
<th>4. Transaction Code (Instr. 8)</th>
<th>5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)</th>
<th>6. Date Exercisable and Expiration Date (Month/Day/Year)</th>
<th>7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)</th>
<th>8. Price of Derivative Security (Instr. 5)</th>
<th>9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)</th>
<th>10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>11. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Restricted Stock Units</td>
<td>(1)</td>
<td>09/01/2020</td>
<td></td>
<td>M</td>
<td>3,750</td>
<td>(1)</td>
<td>(3)</td>
<td>Common Stock</td>
<td>3,750 $0.00</td>
<td></td>
<td>D</td>
</tr>
</tbody>
</table>

Explanation of Responses:
1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
2. Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 3,750 shares of Common Stock underlying the Reporting Person's RSUs.
3. The shares of Common Stock underlying the RSU's vested with respect to 1/4th of the shares on March 1, 2020 and thereafter 1/4th of the remaining underlying shares shall vest in semi-annual installments over 3 years from March 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSU's are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.

Remarks:

/s/ Tricia Suvari, as Attorney-in-Fact 09/03/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).


Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 8 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.